EyePoint, Inc. filed a current report on August 17, 2026, disclosing that topline data from its LUGANO pivotal Phase 3 clinical trial, evaluating DURAVYU for wet age-related macular degeneration, had been released to the public.

Key Highlights

  • Trial name: The clinical study disclosed is LUGANO, described as one of EyePoint's pivotal Phase 3 clinical trials.
  • Product under evaluation: DURAVYU is the candidate being studied for the treatment of wet age-related macular degeneration (wet AMD).
  • Data stage: The filing describes the released data as topline data from the Phase 3 program.
  • Investor presentation: EyePoint also posted an updated investor presentation, filed as Exhibit 99.2, on the same date.
  • Signing officer: The report was signed by George O. Elston, Executive Vice President and Chief Financial Officer, on August 17, 2026.
  • Exchange listing: EyePoint common stock, par value $0.001, trades on NASDAQ:EYPT on the Nasdaq Global Market.

EyePoint Announces LUGANO Trial Results for DURAVYU in Wet AMD

According to the filing, EyePoint, Inc., a Delaware-incorporated biopharmaceutical company headquartered at 480 Pleasant Street, Watertown, Massachusetts, issued a press release on August 17, 2026, announcing topline data from LUGANO, which the company described as one of its pivotal Phase 3 clinical trials. The trial is evaluating DURAVYU, EyePoint's branded candidate, for the treatment of wet age-related macular degeneration, a serious eye condition that can lead to vision loss.

The current report was filed under Item 8.01 (Other Events) and attaches the press release as Exhibit 99.1. The filing incorporates that press release by reference but does not itself reproduce the specific topline data findings. Separately, the company disclosed that an updated investor presentation was filed as Exhibit 99.2 and incorporated by reference into the same report. The filing does not contain commentary on the direction or interpretation of the trial results; readers are directed to the attached exhibits for the underlying data disclosures.

The report was executed on behalf of EyePoint, Inc. by George O. Elston, identified in the filing as Executive Vice President and Chief Financial Officer. The company's common stock carries a par value of $0.001 per share and is listed on the Nasdaq Global Market under the trading symbol EYPT.

What Was Disclosed

EyePoint, Inc. filed an 8-K on August 17, 2026, reporting topline data from its LUGANO Phase 3 trial of DURAVYU for wet AMD, and attaching both a press release and an updated investor presentation as exhibits incorporated by reference.